Q1 results for uniQure N.V.


Dutch biotech uniQure N.V. (QURE) reports Q1 results. License and collaboration revenues: EURO1.2M; R&D expenses: EURO6.2M (+72.2%); net loss: EURO7.8M (-50.0%); loss/share: EURO0.52 (+1.9%); cash and equivalents: EURO77.5M. Increase in R&D expenses was due to the expansion of activities in the hemophilia B program.

Signed a strategic collaboration with 4D Molecular Therapeutics for exclusive access to 4D's adeno-associated viral (AAV) vector discovery and optimization technology for gene delivery to the central nervous system and liver.

Commercialization partner Chiesi advanced the launch of Glybera by establishing centers of excellence and working on reimbursement issues.

Hemophilia B AAV5 candidate Phase 1/2 trial expected to start by the end of the year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs